Drug intelligence / Profile preview

CAR13

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intracerebroventricular, Intratumoral, Intracavity, Intracranial

Overview

CAR13 is an engineered Chimeric Antigen Receptor (CAR) T cell therapy designed to treat Anaplastic Thyroid Carcinoma (ATC). It targets Interleukin-13 receptor subunit alpha-2 (IL13Rα2), a protein found to be highly expressed in ATC cells. Upon binding to IL13Rα2 on tumor cells, CAR13 T cells are activated, leading to proliferation, cytokine production, and subsequent cytolysis (killing) of the tumor cells. Preclinical studies in xenograft mouse models of poorly differentiated thyroid cancer have demonstrated its anti-tumor potency and tumor infiltration.

Targets

IL13RA2 (Interleukin-13 receptor subunit alpha 2)

Beyond the preview

Go deeper on CAR13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR13.

Explore the full profile